Michael Pfeilstöcker

8.7k total citations · 1 hit paper
83 papers, 2.3k citations indexed

About

Michael Pfeilstöcker is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Michael Pfeilstöcker has authored 83 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 43 papers in Genetics and 18 papers in Molecular Biology. Recurrent topics in Michael Pfeilstöcker's work include Acute Myeloid Leukemia Research (59 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Michael Pfeilstöcker is often cited by papers focused on Acute Myeloid Leukemia Research (59 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Michael Pfeilstöcker collaborates with scholars based in Austria, Germany and Italy. Michael Pfeilstöcker's co-authors include Thomas Nösslinger, Peter Valent, Reinhard Stauder, Wolfgang R. Sperr, Otto Krieger, Christa Fonatsch, Friedrich Wimazal, Detlef Haase, Aristoteles Giagounidis and Michael Lübbert and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael Pfeilstöcker

74 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

2007 540 citations Ulrich Germing, Julie Schanz et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Pfeilstöcker Austria	22	1.9k	942	594	284	266	83	2.3k
Robert Schoch Germany	12	1.7k 0.9×	604 0.6×	972 1.6×	352 1.2×	282 1.1×	21	2.3k
Itsuro Jinnai Japan	20	1.9k 1.0×	647 0.7×	621 1.0×	729 2.6×	277 1.0×	79	2.3k
Denise A. Wells United States	18	1.2k 0.6×	456 0.5×	237 0.4×	204 0.7×	174 0.7×	47	1.5k
Jay T. Backstrom United States	14	3.2k 1.7×	1.0k 1.1×	1.7k 2.9×	638 2.2×	387 1.5×	46	3.8k
Hartmut Doehner Germany	9	1.9k 1.0×	572 0.6×	806 1.4×	606 2.1×	402 1.5×	32	2.2k
Guillermo Montalban‐Bravo United States	23	1.5k 0.8×	519 0.6×	766 1.3×	363 1.3×	361 1.4×	202	1.9k
Tomas Ahlgren Sweden	17	967 0.5×	436 0.5×	353 0.6×	253 0.9×	152 0.6×	31	1.3k
Emmanuel C. Besa United States	23	1.0k 0.5×	693 0.7×	425 0.7×	139 0.5×	167 0.6×	68	1.7k
FR Davey United States	14	1.1k 0.6×	391 0.4×	372 0.6×	722 2.5×	266 1.0×	32	1.6k
Inger Marie S. Dahl Norway	20	1.1k 0.6×	398 0.4×	696 1.2×	98 0.3×	427 1.6×	37	1.7k

Countries citing papers authored by Michael Pfeilstöcker

Since Specialization

Citations

This map shows the geographic impact of Michael Pfeilstöcker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Pfeilstöcker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Pfeilstöcker more than expected).

Fields of papers citing papers by Michael Pfeilstöcker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Pfeilstöcker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Pfeilstöcker. The network helps show where Michael Pfeilstöcker may publish in the future.

Co-authorship network of co-authors of Michael Pfeilstöcker

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Pfeilstöcker. A scholar is included among the top collaborators of Michael Pfeilstöcker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Pfeilstöcker. Michael Pfeilstöcker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nachtkamp, Kathrin, Franz Schulz, Aldona Kasprzak, et al.. (2025). Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS). Annals of Hematology. 104(6). 3251–3259.

Voso, Maria Teresa, Stéphane de Botton, Michael Pfeilstöcker, et al.. (2024). A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study.. Journal of Clinical Oncology. 42(16_suppl). 6522–6522. 1 indexed citations

Riedl, Julia, et al.. (2024). Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy– a report of two cases. Annals of Hematology. 104(2). 1249–1253.

Ravandi, Farhad, Hartmut Döhner, Andrew H. Wei, et al.. (2023). Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001. British Journal of Haematology. 204(3). 877–886. 2 indexed citations

Valent, Peter, Irina Sadovnik, Barbara Peter, et al.. (2023). Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives. Expert Review of Hematology. 16(9). 659–670.

Heibl, Sonja, Reinhard Stauder, & Michael Pfeilstöcker. (2021). Is Myelodysplasia a Consequence of Normal Aging?. Current Oncology Reports. 23(12). 142–142. 6 indexed citations

Heibl, Sonja, Bettina Gisslinger, Peter Bettelheim, et al.. (2020). Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers. 12(7). 1891–1891. 4 indexed citations

Tartaglione, Immacolata, Raffaella Origa, Antonis Kattamis, et al.. (2020). Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. Experimental Hematology and Oncology. 9(1). 20–20. 9 indexed citations

Pleyer, Lisa, Ulrich Germing, Wolfgang R. Sperr, et al.. (2014). Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia Research. 38(4). 475–483. 44 indexed citations

10.

Sperr, Wolfgang R., Georg Kemmler, Friedrich Wimazal, et al.. (2014). Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. Journal of Geriatric Oncology. 5(3). 299–306. 16 indexed citations

11.

Pleyer, Lisa, Sonja Burgstaller, Michael Girschikofsky, et al.. (2014). Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of Hematology. 93(11). 1825–1838. 62 indexed citations

12.

Pfeilstöcker, Michael, et al.. (2011). Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. Leukemia Research. 36(2). 132–139. 14 indexed citations

13.

Nösslinger, Thomas, Heinz Tüchler, Ulrich Germing, et al.. (2009). Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Annals of Oncology. 21(1). 120–125. 46 indexed citations

14.

Stauder, Reinhard, Thomas Nösslinger, Michael Pfeilstöcker, et al.. (2008). Impact of Age and Comorbidity in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network. 6(9). 927–934. 27 indexed citations

15.

Fillitz, Michael, Heidrun Karlic, Heinz Tüchler, et al.. (2006). Does mRNA level of microsomal carnitine palmitoyltransferase predict yield of peripheral blood stem cell apheresis?. Annals of Hematology. 85(6). 386–393. 1 indexed citations

16.

Haase, Dagmar, Christian Steidl, Julie Schanz, et al.. (2005). Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.. Blood. 106(11). 787–787. 10 indexed citations

17.

Pfeilstöcker, Michael, Heidrun Karlic, Thomas Nösslinger, et al.. (2002). Assessment of growth and differentiation processes in myelodysplastic syndromes by PCR analysis of Gα16 and 5′-lipoxygenase. Annals of Hematology. 81(11). 632–640. 2 indexed citations

18.

Nösslinger, Thomas, Elisabeth Koller, Heinz Tüchler, et al.. (2001). Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 98(10). 2935–2941. 91 indexed citations

19.

Pfeilstöcker, Michael, et al.. (2001). Effect of the Hemoregulatory Peptide (pEEDCK)2 (pyroGlu‐Glu‐Asp‐Cys‐Lys)2 and MIP‐1α is Reduced in Bone Marrow Cultures from Patients with Chronic Myeloid Leukemia (CML). Stem Cells. 19(4). 321–328. 6 indexed citations

20.

Hengstschläger, Markus, Michael Pfeilstöcker, & Edgar Wawra. (1996). Identification of leukaemic cells in bone marrow and blood samples by a new cytofluorometric assay. British Journal of Cancer. 73(10). 1237–1240. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact